Thr317
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr317  -  CTCF (human)

Site Information
RNHLNTHtGtRPHKC   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 18008369

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:
cervical cancer ( 3 ) , cervical adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
nocodazole ( 3 )

References 

1

Guo A (2010) CST Curation Set: 6268; Year: 2010; Biosample/Treatment: cell line, 293/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

2

Guo A (2010) CST Curation Set: 6270; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

3

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info